How long until you start losing weight on Wegovy

Early weight change (weeks 1–4) is real but modest — the starting 0.25mg dose is there to let your body adjust, not to deliver peak results.
Average losses in the STEP 1 trial reached roughly 15% of body weight over 68 weeks at the 2.4mg maintenance dose.
The pace of loss varies between individuals depending on starting weight, dose reached, diet, activity and how the body responds to semaglutide.
NICE recommends reviewing progress at six months: if less than 5% weight loss has occurred on the maintenance dose, continuing treatment is reconsidered.

Most people begin to lose some weight within the first four weeks of starting Wegovy, though meaningful, sustained loss typically builds over several months as the dose increases. The STEP 1 trial, published in the New England Journal of Medicine, found participants lost an average of around 15% of their body weight over 68 weeks — a figure that reflects the full titration journey, not the first injection. Wegovy is a prescription-only medicine; a prescriber assesses whether it is clinically suitable for you before it can be supplied.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence (and real-world experience) tells us about Wegovy's timeline

What the trial data show about the first weeks and months

The STEP 1 trial is the most cited evidence base for Wegovy's weight-loss timeline, and it is worth reading carefully. Over 68 weeks, adults with obesity who took semaglutide 2.4mg alongside lifestyle changes lost around 15% of their body weight on average, versus just under 3% for those on placebo. But that headline figure tells you where participants ended up, not how quickly the journey moved.

Weight loss in STEP 1 was gradual and roughly linear through the dose-escalation period, then continued at a slower rate once 2.4mg maintenance was reached. The steepest drops tended to coincide with dose increases, because higher doses suppress appetite more effectively. Participants who started at a heavier baseline often saw larger absolute losses in kilograms early on, even when percentage loss was similar. If you are wondering how fast you start losing weight on Wegovy, early weeks bring real but small reductions, a few hundred grams to a kilogram or two is common in weeks one to four. The body is still adapting, gastric emptying is slowing, appetite signals are beginning to shift.

For a fuller picture of how Wegovy works over time, the Wegovy timeline page walks through each phase of the titration period in more detail.

Why the 0.25mg starting dose feels slow, and why that is the point

The first four weeks of Wegovy begin at 0.25mg, a dose chosen for tolerability rather than therapeutic effect. Nausea, indigestion and loose stools are the most common early side effects, and starting low gives the gastrointestinal system time to settle before the dose climbs. Expecting dramatic weight loss at this stage sets up unnecessary disappointment.

The standard titration moves through 0.5mg, then 1.0mg, then 1.7mg, before reaching the 2.4mg maintenance dose, each step taking approximately four weeks, with the prescriber's guidance setting the pace. The NHS semaglutide page summarises this schedule clearly and is worth bookmarking alongside your Patient Information Leaflet. Some people find side effects mean they stay at an intermediate dose longer; others move through the rungs without much difficulty. Neither pattern predicts the eventual outcome.

The practical upshot: if you order Wegovy and start your first pen at the beginning of the month, you should not expect to feel noticeably different by payday. The medicine is doing quieter work in those early weeks (resetting appetite signals, slowing gastric emptying) and the visible results tend to follow later.

When most people notice a real difference

Clinical experience and the trial data broadly agree: noticeable, sustained weight loss becomes apparent for most people somewhere between weeks eight and sixteen, which corresponds to the 1.0mg–1.7mg dose range. By the time 2.4mg maintenance is reached (typically around week 17 for those who titrate without delays), average monthly losses of 1–2kg are common, though the range is wide.

Progress is rarely a straight line. Plateaus appear, particularly around dose transitions, and they are a normal part of how the body responds to changes in energy balance, not a sign the medicine has stopped working. People who want to understand how quickly you start losing weight on Wegovy often find that what matters more than week-to-week fluctuations is the direction of travel over three to six months.

NICE's guidance on semaglutide (TA875) sets a clear clinical checkpoint: if someone has not lost at least 5% of their starting weight after six months at the maintenance dose, the clinical team should reassess whether continuing is appropriate. This is not a failure threshold, it is a sensible review point built into the treatment pathway. Our Wegovy overview covers eligibility and what to expect from the full treatment journey.

Separately, if you are weighing up how Wegovy's timeline compares with tirzepatide's, the weight-loss treatments page sets out the options side by side.

Factors that influence how quickly weight loss begins

Starting weight matters: someone starting at 120kg may notice scale movement sooner in absolute terms than someone starting at 85kg, even if the percentage loss follows a similar curve. Diet and activity during treatment shape the result significantly, semaglutide reduces appetite and slows gastric emptying, but it works alongside a reduced-calorie diet, not instead of one. Protein intake, hydration and strength activity all support the process; specific plans are best discussed with a prescriber or dietitian rather than followed from generic guidance.

Individual variation in how the body responds to semaglutide is also real. Some people are highly responsive from the first dose increase; others reach full effect only at 2.4mg or need longer at maintenance. For those asking how long until you lose weight on Wegovy, there is no reliable way to predict in advance which group you will fall into, which is one reason why clinical review throughout treatment (not just at the start) matters.

Questions about cost are understandably part of the decision. The Wegovy cost page explains what private treatment typically involves and what an all-inclusive price should cover. For anything more specific to your situation, our team is available seven days a week.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions